Literature DB >> 24342897

Immediate cooling does not prevent the ex vivo hydrolysis of L-asparagine by asparaginase.

Claudia Lanvers-Kaminsky1, Petra Schulze Westhoff, Maurizio DʼIncalci, Massimo Zucchetti, Joachim Boos.   

Abstract

BACKGROUND: Monitoring of asparagine (ASN) during asparaginase (ASE) treatment directly links to the antileukemic effect of ASE but is challenging because of ASE-induced ex vivo hydrolysis of ASN. Assuming that ASE is not active at 4°C, immediate cooling of blood samples became the accepted method for ASN determination during ASE therapy.
METHODS: To evaluate the effect of immediate sample cooling on the ex vivo hydrolysis of ASN by ASE the degradation of C4-ASN in whole blood, spiked with different ASE concentrations were analyzed HPLC-MS. C4-ASN and ASE were added either to blood at 4°C or to blood at 37°C, which was instantly cooled down to 4°C.
RESULTS: Immediate cooling did not prevent the ex vivo hydrolysis of ASN by ASE. The rate of ASN degradation to aspartic acid depended on the amount of ASE, ASE preparation, and time. Spiked into blood at 4°C 100 U/L native E. coli ASE already immediately degraded 100% of C4-ASN, whereas 10 U/L reduced the amount of C4-ASN by 30%. Spiked into blood at 37°C, which was immediately cooled thereafter, 10 U/L native E. coli ASE hydrolyzed 60% of C4-ASN and 1 U/L between 5% and 10% of C4-ASN. Concentrations of aspartic acid increased in parallel with ASN degradation. In addition, the ex vivo hydrolysis also affected concentrations of glutamine and glutamic acid.
CONCLUSIONS: Cooling of blood samples did not inactivate ASE. Thus, to evaluate the precise pharmacodynamics of ASE, alternative methods for effective ASE inactivation at the time of blood withdrawal are needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24342897     DOI: 10.1097/FTD.0000000000000030

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

1.  Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.

Authors:  Reuven J Schore; Meenakshi Devidas; Archie Bleyer; Gregory H Reaman; Naomi Winick; Mignon L Loh; Elizabeth A Raetz; William L Carroll; Stephen P Hunger; Anne L Angiolillo
Journal:  Leuk Lymphoma       Date:  2019-01-10

2.  Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.

Authors:  Inge M van der Sluis; Lynda M Vrooman; Rob Pieters; Andre Baruchel; Gabriele Escherich; Nicholas Goulden; Veerle Mondelaers; Jose Sanchez de Toledo; Carmelo Rizzari; Lewis B Silverman; James A Whitlock
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

3.  A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

Authors:  Wing H Tong; Rob Pieters; Gertjan J L Kaspers; D Maroeska W M te Loo; Marc B Bierings; Cor van den Bos; Wouter J W Kollen; Wim C J Hop; Claudia Lanvers-Kaminsky; Mary V Relling; Wim J E Tissing; Inge M van der Sluis
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

4.  Comment on "Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase".

Authors:  Wing H Tong
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-01       Impact factor: 3.333

5.  Comment on Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions.

Authors:  Wing H Tong
Journal:  J Oncol Pharm Pract       Date:  2021-04-13       Impact factor: 1.809

6.  Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.

Authors:  Alexander Karachunskiy; Gesche Tallen; Julia Roumiantseva; Svetlana Lagoiko; Almira Chervova; Arend von Stackelberg; Olga Aleinikova; Oleg Bydanov; Lyudmila Bajdun; Tatiana Nasedkina; Natalia Korepanova; Sergei Kuznetsov; Galina Novichkova; Marina Goroshkova; Dmitry Litvinov; Natalia Myakova; Natalia Ponomareva; Evgeniya Inyushkina; Konstantin Kondratchik; Julia Abugova; Larisa Fechina; Oleg Arakaev; Alexander Karelin; Vladimir Lebedev; Natalia Judina; Gusel Scharapova; Irina Spichak; Anastasia Shamardina; Olga Ryskal; Alexander Shapochnik; Alexander Rumjanzew; Joachim Boos; Günter Henze
Journal:  J Cancer Res Clin Oncol       Date:  2019-03-06       Impact factor: 4.553

7.  Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian Center.

Authors:  Daiane Keller Cecconello; Ciliana Rechenmacher; Isabel Werlang; Priscila Pini Zenatti; Jose Andres Yunes; Ana Paula Alegretti; Claudia Lanvers-Kaminsky; Liane Esteves Daudt; Mariana Bohns Michalowski
Journal:  Sci Rep       Date:  2020-12-08       Impact factor: 4.379

8.  Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study.

Authors:  Line Stensig Lynggaard; Cecilie Utke Rank; Stefan Nygaard Hansen; Sofie Gottschalk Højfeldt; Louise Tram Henriksen; Kirsten Brunsvig Jarvis; Susanna Ranta; Riitta Niinimäki; Arja Harila-Saari; Benjamin O Wolthers; Thomas L Frandsen; Mats Heyman; Kjeld Schmiegelow; Birgitte Klug Albertsen
Journal:  Blood Adv       Date:  2022-01-11

9.  Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?

Authors:  Inge M van der Sluis; Yves Bertrand; André Baruchel; Rob Pieters
Journal:  Br J Haematol       Date:  2022-07-20       Impact factor: 8.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.